Stock performance snapshot and recent trading context Charles River Laboratories International (CRL) has recently drawn investor attention after a period of mixed returns, including a gain of 2.9% ...

The complete response letter (CRL) was issued based on a pre-approval inspection at a third-party fill/finish manufacturer. Similar to other recent CRLs, this decision was made not based on the drug’s ...

Lab services company Charles River Laboratories (NYSE:CRL) reported Q1 CY2026 results topping the market’s revenue expectations, with sales up 1.2% year on year to $995.8 million. Its non-GAAP profit ...

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a ...

FDA’s CRL focused on CMC deficiencies, with no objections to clinical safety or efficacy, enabling a resubmission pathway primarily driven by manufacturing remediation. The NDA was accepted in October ...

Oakmark Funds, advised by Harris Associates, released its “Oakmark Equity and Income Fund” Q2 2025 investor letter. A copy of the letter can be downloaded here. The equity portfolio returned 4.67% in ...

Charles River Laboratories (CRL) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended September 2025. This widely-known consensus ...

Charles River Laboratories International Inc (NYSE:CRL) reported second-quarter 2024 revenue of $1.03 billion on Wednesday, a decrease of 3.2% year over year, beating the consensus of $1.024 billion.

Investors in Charles River Laboratories International Inc. (Symbol: CRL) saw new options become available today, for the July 2024 expiration. One of the key inputs that goes into the price an option ...